MAPT Exon 10 RNAi Agent for 4R-Tau Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for 4R-tauopathies are limited to symptom alleviation and do not address the underlying issue of 4R-tau expression, necessitating the development of agents that can efficiently inhibit or adjust the expression of 4R-tau.
Innovation Solution
The use of RNAi compositions that target a specific hotspot region within exon 10 of the MAPT gene, leading to the RNA-induced silencing complex (RISC)-mediated cleavage of 4R-tau RNA transcripts, thereby inhibiting their expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for 4R-tauopathies, then symptom alleviation is achieved, but the underlying issue of 4R-tau expression is not addressed
Solution Approach 1:
The patent extracts and targets the specific 4R-tau RNA transcript sequence (exon 10 hotspot region) using RNAi compositions. By designing siRNAs that specifically bind to and degrade the 4R-tau mRNA, the invention removes the harmful molecular component from the system, thereby addressing the underlying expression issue rather than merely alleviating symptoms.
Solution Approach 2:
The patent changes the expression parameter of 4R-tau by using RNA interference to reduce transcript levels. The RNAi compositions are designed to achieve specific knockdown percentages (25-95% inhibition), directly modifying the quantitative expression parameter of the pathogenic protein to restore normal cellular function.
2Productivity
If RNAi compositions target exon 10 hotspot region of MAPT gene, then 4R-tau transcript expression is significantly inhibited, but off-target effects and safety concerns may arise
Solution Approach 1:
The patent applies local quality by designing siRNAs with specific sequence complementarity to the exon 10 hotspot region of the MAPT gene. The siRNAs are engineered to match only the 4R-tau isoform sequence at this specific location, ensuring selective degradation of 4R-tau transcripts while preserving 3R-tau expression and minimizing off-target effects through precise local targeting.
Solution Approach 2:
The patent incorporates feedback mechanisms through careful design of the siRNA sequences to account for potential off-target binding. The exon 10 hotspot region was selected based on its unique sequence characteristics that provide high specificity. Additionally, the patent considers cellular feedback responses and adjusts the siRNA design to maintain safety while achieving effective knockdown.
3Reliability
If 4R-tau expression is inhibited, then 4R-tauopathy symptoms may be addressed, but the complexity of RNAi composition design and delivery increases
Solution Approach 1:
The patent segments the complex task of 4R-tau inhibition into manageable components: (1) identification of the exon 10 hotspot region as the target, (2) design of specific siRNA sequences complementary to this region, (3) optimization of siRNA structure for stability and efficacy, and (4) development of delivery mechanisms. This segmentation allows systematic development and optimization of each component independently.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAi compositions achieve significant inhibition of 4R-tau transcript expression, with reductions ranging from 25% to 95% compared to control levels, effectively addressing the challenge of 4R-tau-associated disorders.
Implementation Method 1
RNAi compositions that effect the RNA-induced silencing complex (RISC)-mediated cleavage of 4R-tau RNA transcripts of a MAPT gene
Data Source
AI summary
The disclosure relates to double stranded ribonucleic acid interference (dsRNAi) agents and compositions targeting a hotspot within exon 10 of a microtubule-associated protein tau (MAPT) gene, as well as methods of inhibiting expression of 4R-tau and methods of treating subjects having a 4R-tau-associated disease or disorder, e.g., a 4R-tauopathy such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBD), argyrophilic grain disease (AGD), multiple system tauopathy with presensile dementia (MSTD), globular glial tauopathy (GGT), sporadic (spAD) Alzheimer's disease, or rapidly progressive (rpAD) Alzheimer's disease using such dsRNAi agents and compositions.